C12N 9/226
Class 2 cas enzyme complex
Official title: {Class 2 CAS enzyme complex, e.g. single CAS protein}
C12N9/226 (Class 2 cas enzyme complex) appears on 1,678 US grants and 5,621 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,678
- Published applications
- 5,621
- Assignees
- 1,303
- Inventors
- 9,072
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 3 | 0 |
| 1988 | 1 | 0 |
| 1989 | 3 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 9 | 0 |
| 1993 | 7 | 0 |
| 1994 | 3 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 6 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 8 | 34 |
| 2015 | 7 | 36 |
| 2016 | 10 | 101 |
| 2017 | 23 | 89 |
| 2018 | 50 | 105 |
| 2019 | 66 | 201 |
| 2020 | 93 | 513 |
| 2021 | 123 | 612 |
| 2022 | 188 | 655 |
| 2023 | 242 | 811 |
| 2024 | 285 | 989 |
| 2025 | 354 | 819 |
| 2026 | 193 | 654 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Adenine deaminases and compositions, systems, and methods thereof29 Sep 2026US 12,747,436 B2Profluent Bio Inc.
- Utilization of gene targeting antibody fusion proteins to perform in vivo therapeutic gene editing22 Sep 2026US 12,741,035 B2Baylor College of Medicine
- Conjugates of guide RNA-Cas protein complex22 Sep 2026US 12,742,162 B2
- Modified nucleases22 Sep 2026US 12,742,163 B2Artisan Developments Labs, INC
- CRISPR-associated systems and components25 Aug 2026US 12,716,060 B2Arbor Biotechnologies, Inc.
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Methods of preventing on-target genotoxicity induced by nucleases8 Oct 2026US 2026/0306552 A1Chu De Bordeaux
- Base editing approaches to treat abca4-associated stargardt disease8 Oct 2026US 2026/0306670 A1Massachusetts Eye and Ear Infirmary
- Transcription factor 4 gene editing system8 Oct 2026US 2026/0306671 A1The Regents of the University of California
- Novel regulatory cassettes for specific expression of genes in muscle stem cells8 Oct 2026US 2026/0306674 A1University of Washington
Most cited
By later US patents
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014
- Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains568US 8,993,233 B2Massachusetts Institute of Technology · 2015
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014